Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of TQC2731 in inadequately controlled severe asthma
CTR20221541Phase 2Completed
- Sponsor
- Nanjing Shunxin Pharmaceutical
- Start
- Sep 2022
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of bosakitug in severe asthma, sponsored by Nanjing Shunxin Pharmaceutical. Started Sep 2022; status: completed.
02
Drugs
bosakitug
03
Conditions
severe asthma
Beyond the preview
Go deeper on CTR20221541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221541.